Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BGB-11417 + BGB-16673 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BGB-11417 | BGB 11417|BGB11417|Sonrotoclax | BCL2 inhibitor 27 | BGB-11417 selectively inhibits Bcl2, which potentially leads to decreased tumor cell proliferation and inhibition of tumor growth (Cancer Res 2020;80(16 Suppl):Abstract nr 3077). | |
BGB-16673 | BGB16673|BGB 16673 | BTK inhibitor 38 | BGB-16673 is a proteolysis-targeted chimera (PROTAC) that binds to Bruton's tyrosine kinase (BTK) and targets it for degradation, potentially leading to growth inhibition of BTK-expressing tumor cells (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06634589 | Phase Ib/II | BGB-16673 + Zanubrutinib BGB-11417 + BGB-16673 | A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies | Recruiting | USA | POL | NZL | ITA | DEU | AUS | 1 |